We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

HemoSonics Demonstrates Breakthrough in Point-Of-Care Viscoelastic Hemostasis Testing

By HospiMedica International staff writers
Posted on 08 Aug 2024
Print article
Image: FDA recently granted HemoSonics expanded use of its critical bleeding management system with Special 510(k) clearance (Photo courtesy of HemoSonics)
Image: FDA recently granted HemoSonics expanded use of its critical bleeding management system with Special 510(k) clearance (Photo courtesy of HemoSonics)

At ADLM 2024, HemoSonics (Durham, NC, USA) is demonstrating its Quantra Hemostasis System which has the broadest range of FDA-cleared indications for use in its category and is cleared for use with arterial and venous blood samples in cardiac, trauma, liver, and major orthopedic surgery patients.

HemoSonics' Quantra Hemostasis System consists of the Quantra Hemostasis Analyzer with QPlus and QStat Cartridges, which enable clinicians to deliver patient-centered decisions on bleeding management that improve care and optimize blood product usage. The Quantra System is FDA-cleared for use in point-of-care settings such as operating rooms, intensive care units, and in hospital laboratories, enabling hospitals to standardize use institution-wide with greater operational efficiency. The Quantra System allows healthcare professionals to make individualized and evidence-based decisions on how to manage a bleeding patient and give a patient only medically appropriate therapy – an approach that supports global initiatives to reduce inappropriate transfusions of blood products.

The Quantra System requires minimal resources to maintain, is easy to operate and interpret, and provides fast, comprehensive whole-blood coagulation analysis at the point of care or in laboratory-based settings, typically in less than 15 minutes. A recent study showed that the implementation of the Quantra Hemostasis Analyzer with the QPlus Cartridge reduced utilization of blood components by up to 90%, allowing greater availability for those patients truly in need. In addition, the cost of blood products decreased by 41%. HemoSonics' QStat Cartridge used with the Quantra Hemostasis Analyzer first received 510(k) clearance from the U.S. FDA in 2022 for use in venous whole blood samples. In April this year, HemoSonics received Special 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded use of arterial blood samples with its Quantra QStat Cartridge.

Related Links:
HemoSonics

Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Multi-Parameter Patient Monitor
S90
New
Total Ankle Prosthesis
SALTO TALARIS

Print article

Channels

Critical Care

view channel
Image: The Atmo Gas Capsule measures gases as it travels through the GI tract and transmits the data wirelessly (Photo courtesy of Atmo Biosciences)

Ingestible Smart Capsule for Chemical Sensing in the Gut Moves Closer to Market

Intestinal gases are associated with several health conditions, including colon cancer, irritable bowel syndrome, and inflammatory bowel disease, and they have the potential to serve as crucial biomarkers... Read more

Surgical Techniques

view channel
Image: Intravascular imaging can improve outcomes for complex stenting procedures in patients with high-risk calcified coronary artery disease (Photo courtesy of Shutterstock)

Intravascular Imaging for Guiding Stent Implantation Ensures Safer Stenting Procedures

Patients diagnosed with coronary artery disease, which is caused by plaque accumulation within the arteries leading to chest pain, shortness of breath, and potential heart attacks, frequently undergo percutaneous... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more